|14th January 2021||Trevor Hallam||19,405||Exercise of derivative||$4.36||$84,605.80|
|28th December 2020||Trevor Hallam||2,393||Exercise of derivative||$4.36||$10,433.48|
|28th December 2020||Trevor Hallam||2,393||Open or private sale||$22.37||$53,530.21|
|10th December 2020||John Gordon Freund||118,735||Other acquisition or disposition||$0.00|
|10th December 2020||John Gordon Freund||56,327||Other acquisition or disposition||$0.00|
|3rd December 2020||John Gordon Freund||47,886||Open or private sale||$23.39||$1,120,197.20|
|2nd December 2020||John Gordon Freund||100,000||Open or private sale||$23.28||$2,328,480.00|
|27th November 2020||Trevor Hallam||2,393||Exercise of derivative||$4.36||$10,433.48|
|27th November 2020||Trevor Hallam||2,393||Open or private sale||$17.01||$40,713.07|
|5th November 2020||Trevor Hallam||16,751||Exercise of derivative||$4.36||$73,034.36|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility.